Elif Erkan1, Xueheng Zhao2, Kenneth Setchell2, Prasad Devarajan3. 1. Division of Pediatric Nephrology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue MLC 7022, Cincinnati, OH, 45229, USA. Elif.Erkan@cchmc.org. 2. Department of Pathology, Children's Hospital of Cincinnati, Cincinnati, OH, USA. 3. Division of Pediatric Nephrology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue MLC 7022, Cincinnati, OH, 45229, USA.
Abstract
BACKGROUND: Focal segmental glomerulosclerosis (FSGS) accounts for the majority of new-onset end-stage renal disease (ESRD) during adolescence. FSGS treatment is a great challenge for pediatric nephrologists due to intertwined molecular pathways underlining its complex pathophysiology. There is emerging evidence showing that perturbed lipid metabolism plays a role in the pathophysiology of FSGS. METHODS: We postulate that the nephrotic milieu in FSGS differs from minimal change disease (MCD) and that urinary lipidomics can be used as a tool for early diagnosis of FSGS. We explored the urinary lipid profile of patients with FSGS and MCD using an unbiased metabolomics approach. RESULTS: We discovered a unique lipid signature characterized by increased concentration of fatty acid (FA) and lysophosphatidylcholines (LPC) and a decrease in urinary concentration of phosphatidylcholine (PC) in patients with FSGS. These findings indicate increased metabolism of membrane phospholipid PC by phospholipase A2 (PLA2), resulting in higher urinary concentrations of LPC and FA. CONCLUSIONS: We propose that increased PC by-products can be used as a biomarker to diagnose FSGS and shed light on the mechanism of tubular and podocyte damage. Validation of identified urinary lipids as a biomarker in predicting the diagnosis and progression of FSGS in a larger patient population is warranted.
BACKGROUND:Focal segmental glomerulosclerosis (FSGS) accounts for the majority of new-onset end-stage renal disease (ESRD) during adolescence. FSGS treatment is a great challenge for pediatric nephrologists due to intertwined molecular pathways underlining its complex pathophysiology. There is emerging evidence showing that perturbed lipid metabolism plays a role in the pathophysiology of FSGS. METHODS: We postulate that the nephrotic milieu in FSGS differs from minimal change disease (MCD) and that urinary lipidomics can be used as a tool for early diagnosis of FSGS. We explored the urinary lipid profile of patients with FSGS and MCD using an unbiased metabolomics approach. RESULTS: We discovered a unique lipid signature characterized by increased concentration of fatty acid (FA) and lysophosphatidylcholines (LPC) and a decrease in urinary concentration of phosphatidylcholine (PC) in patients with FSGS. These findings indicate increased metabolism of membrane phospholipidPC by phospholipase A2 (PLA2), resulting in higher urinary concentrations of LPC and FA. CONCLUSIONS: We propose that increased PC by-products can be used as a biomarker to diagnose FSGS and shed light on the mechanism of tubular and podocyte damage. Validation of identified urinary lipids as a biomarker in predicting the diagnosis and progression of FSGS in a larger patient population is warranted.
Authors: Kirill A Veselkov; Lisa K Vingara; Perrine Masson; Steven L Robinette; Elizabeth Want; Jia V Li; Richard H Barton; Claire Boursier-Neyret; Bernard Walther; Timothy M Ebbels; István Pelczer; Elaine Holmes; John C Lindon; Jeremy K Nicholson Journal: Anal Chem Date: 2011-07-05 Impact factor: 6.986
Authors: Sanju A Varghese; T Brian Powell; Milos N Budisavljevic; Jim C Oates; John R Raymond; Jonas S Almeida; John M Arthur Journal: J Am Soc Nephrol Date: 2007-02-14 Impact factor: 10.121
Authors: Janina Müller-Deile; George Sarau; Ahmed M Kotb; Christian Jaremenko; Ulrike E Rolle-Kampczyk; Christoph Daniel; Stefan Kalkhof; Silke H Christiansen; Mario Schiffer Journal: Sci Rep Date: 2021-02-25 Impact factor: 4.379